Trial Profile
Peg-IFN-alfa 2b/Ribavirin/Vaniprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and duration of therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Vaniprevir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 05 Mar 2015 New trial record